ClinicalTrials.gg

Program

eltrekibart

Also written as “LY3041658”, “Eltrekibart” and “LY3041658 (SC)”.

Its studies are mostly in Hidradenitis Suppurativa · Colitis, Ulcerative · Psoriasis, led by Eli Lilly.

Furthest: phase 2, since Jul 29, 20207 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly71 open or runningphase 2since Jul 29, 2020May 22, 2014none ahead
  • Named in Eli Lilly’s own pipeline as Eltrekibart, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2014First study: phase 1 study in HealthyFirst studyNCT02148627 · 54 enrolled · United States
  2. Sep 7, 2016Phase 1 study in Skin DiseasesNCT02896868 · 60 enrolled · United States
  3. Jul 29, 2020Phase 2 study in Hidradenitis SuppurativaNCT04493502 · 72 enrolled · United States, Australia
  4. Dec 3, 2020Phase 1 study in HealthyNCT04653168 · 16 enrolled · Singapore
  5. Sep 14, 2023Phase 2 study in Hidradenitis SuppurativaNCT06046729 · 352 enrolled · United States, Australia, Canada and more
  6. Sep 13, 2024Phase 2 study in Colitis, UlcerativeNCT06598943 · 143 enrolled · United States, Argentina, Belgium and more
  7. Apr 16, 2026Phase 1 study in HealthyNCT07545590 · 60 enrolled · Singapore

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07545590Healthy · Singapore1CompletedSep 22, 202660
NCT06598943Colitis, Ulcerative · United States, Argentina, Belgium and more2Active, not recruitingAug 3, 2026143
NCT06046729Hidradenitis Suppurativa · United States, Australia, Canada and more2CompletedSep 30, 2025352
NCT04653168Healthy · Singapore1CompletedMay 28, 202116
NCT04493502Hidradenitis Suppurativa · United States, Australia2CompletedMar 15, 202272
NCT02896868Skin Diseases · United States1CompletedMar 19, 201960
NCT02148627Healthy · United States1CompletedFeb 11, 201754

How it is read

Names in the registry

  • “LY3041658”, 5 entries
  • “Eltrekibart”, 2 entries
  • “LY3041658 (SC)”, 1 entry
  • “LY3041658 (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.